Aktienanalyse zu OKYO Pharma Ltd (OKYO)OKYOOKYO Pharma Ltd

OKYO Pharma Limited is a United Kingdom-based clinical-stage biopharmaceutical company developing therapies for the treatment of dry eye disease (DED) and neuropathic corneal pain (NCP). The Company is focused on the discovery and development of novel molecules to treat neuropathic corneal pain and dry eye disease. Its research program focuses on a novel G Protein-Coupled Receptor (GPCR). The Company’s lead candidate, urcosimod, is a non-steroidal anti-inflammatory and non-opioid analgesic. Urcosimod consists of a 10-mer C-terminal Chemerin sequence, a linker (PEG-8), and Palmitic acid. It has completed a Phase II trial in patients with DED and NCP. The Company also plans to evaluate its potential in benefiting patients with ocular neuropathic pain, uveitis and allergic conjunctivitis. It is also evaluating OK-201, a bovine adrenal medulla (BAM), lipidated-peptide preclinical analogue candidate that is in the developmental stage. It operates in the Healthcare sector (BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES industry).

OKYO Pharma Ltd is a good buy right now due to its recent price increase of 8.44% over the last 5 days and the chairman's recent purchase of 25,000 shares at $1.40, indicating strong insider confidence. The stock is currently priced at $1.67, and the projected trajectory suggests a potential increase of 152.72%, which presents a significant upside opportunity. However, the forward P/E ratio is at 0, indicating uncertainty in earnings expectations, which is a notable risk.